Research programme: cell based therapeutics - Cell Source

Drug Profile

Research programme: cell based therapeutics - Cell Source

Alternative Names: Anti Third Party Veto Cell - Cell Source; Organsource; T-central memory Veto Cell - Cell Source; TCM Veto Cell - Cell Source

Latest Information Update: 09 Nov 2015

Price : $50

At a glance

  • Originator Weizmann Institute of Science
  • Developer Cell Source
  • Class Cell therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Transplant rejection

Most Recent Events

  • 04 Nov 2015 Cell based therapeutics - Cell Source are available for licensing as of 04 Nov 2015. www.cell-source.com
  • 04 Nov 2015 Cell Source files for patent protection with the United States Patent Office for Veto Cell technology in USA
  • 23 Oct 2014 Italian Medicine Association approves IND application for megadose drug combination in Transplant rejection (Prevention)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top